Blockade of adenosine A2A receptors downregulates DARPP-32 but increases ERK1/2 activity in striatum of dopamine deficient "weaver" mouse

Neurochemistry International

Volumn 56, Issue 2, 2010, Pages 245-249

  Botsakis, Konstantinos ^a   Pavlou, Ourania ^a   Poulou, Paraskevi D ^b   Matsokis, Nikolaos ^a   Angelatou Fevronia, F ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

" Weaver" mutant; A2A receptors; DARPP 32; Dopamine deficiency; ERK1 2

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOPROTEIN DARPP 32; DOPAMINE; MITOGEN ACTIVATED PROTEIN KINASE; PPP1R1B PROTEIN, MOUSE;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE DEFICIENT MOUSE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION;

ANIMALIA;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MICE; MICE, MUTANT STRAINS; PHOSPHORYLATION; RECEPTOR, ADENOSINE A2A;

EID: 77149144806     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.10.007     Document Type: Article

References (52)

1. Bezard E., Gross C.E., Qin L., Gurevich V.V., Benovic J.L., Gurevich E.V. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiol. Dis. 2005, 18:323-335.
2. Bolam J.P., Hanley J.J., Booth P.A., Bevan M.D. Synaptic organization of the basal ganglia. J. Anat. 2000, 196(Pt 4):527-542.
3. Brown P., Gerfen C.R. Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 MAP kinase pathway. J. Comp. Neurol. 2006, 498:415-430.
4. Chen J.F., Pedata F. Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr. Pharm. Des. 2008, 14:1490-1499.
5. Csoka B., Himer L., Selmeczy Z., Vizi E.S., Pacher P., Ledent C., Deitch E.A., Spolarics Z., Nemeth Z.H., Hasko G. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 2008, 22:3491-3499.
6. Derenne A., Arsenault M.L., Austin D.P., Weatherly J.N. Weaver mutant mice exhibit long-term learning deficits under several measures of instrumental behavior. Physiol. Behav. 2007, 92:1002-1009.
7. Ebadi M., Brown-Borg H., El Refaey H., Singh B.B., Garrett S., Shavali S., Sharma S.K. Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. Mol. Brain Res. 2005, 134:67-75.
8. Ekonomou A., Poulou P.D., Matsokis N., Angelatou F. Stimulation of adenosine A2A receptors elicits zif/268 and NMDA epsilon2 subunit mRNA expression in cortex and striatum of the "weaver" mutant mouse, a genetic model of nigrostriatal dopamine deficiency. Neuroscience 2004, 123:1025-1036.
9. Ferré S., Borycz J., Goldberg S.R., Hope B.T., Morales M., Lluis C., Franco R., Ciruela F., Cunha R. Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J. Integr. Neurosci. 2005, 4:445-464.
10. Ferré S., Ciruela F., Canals M., Marcellino D., Burgueno J., Casado V., Hillion J., Torvinen M., Fanelli F., Benedeti P., Goldberg S.R., Bouvier M., Fuxe K., Agnati L., Lluis C., Franco R., Woods A. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuropsychiatric disorders. Parkinsonism Relat. Disord. 2004, 10:265-271.
11. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997, 20:482-487.
12. Ferré S., Quiroz C., Woods A.S., Cunha R., Popoli P., Ciruela F., Lluis C., Franco R., Azdad K., Schiffmann S.N. An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des. 2008, 14:1468-1474.
13. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2 MAP kinase. J. Neurosci. 2002, 22:5042-5054.
14. Gerfen C.R. Basal ganglia. The Rat Nervous System 2004, 445-508. Elsevier Academic, Amsterdam. G. Paxinos (Ed.).
15. Gerfen C.R., Paletzki R., Worley P. Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J. Neurosci. 2008, 28:7113-7120.
16. Ghetti B., Triarhou L.C. Combined degeneration of cerebellar granule cells of midbrain dopamine neurons in the weaver mutant mouse. Progress in Parkinson's Disease Research-2 1992, 375-388. Futura Publishing, Mount Kisco, New York. F. Hefti, W.J. Weiner (Eds.).
17. Graybiel A.M. The basal ganglia. Curr. Biol. 2000, 10:R509-R511.
18. Graybiel A.M. The basal ganglia: learning new tricks and loving it. Curr. Opin. Neurobiol. 2005, 15:638-644.
19. Graybiel A.M. Habits, rituals, and the evaluative brain. Annu. Rev. Neurosci. 2008, 31:359-387.
20. Greengard P., Allen P.B., Nairn A. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999, 23:435-447.
21. Hakansson K., Lindskog M., Pozzi L., Usiello A., Fisone G. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Relat. Disord. 2004, 10:281-286.
22. Hasko G., Linden J., Cronstein B., Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008, 7:759-770.
23. Hasko G., Pacher P. A2A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leukoc. Biol. 2008, 83:447-455.
24. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
25. Jiang H., Jackson-Lewis V., Muthane U., Dollison A., Ferreira M., Espinosa A., Parsons B., Przedborski S. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res. 1993, 613:347-351.
26. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog. Neurobiol. 2009.
27. Morelli M., Fenu S., Pinna A., Di Chiara G. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 1994, 251:21-25.
28. Nicholas A.P., Lubin F.D., Hallett P.J., Vattem P., Ravenscroft P., Bezard E., Zhou S., Fox S.H., Brotchie J.M., Sweatt J.D., Standaert D.G. Striatal histone modifications in models of levodopa-induced dyskinesia. J. Neurochem. 2008, 106:486-494.
29. Peng J., Stevenson F.F., Melov S., DiMonte D.A., Andersen J.K. Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J. Neurosci. 2006, 26:11644-11651.
30. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
31. Quiroz C., Gomes C., Pak A.C., Ribeiro J.A., Goldberg S.R., Hope B.T., Ferré S. Blockade of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation. J. Neurosci. 2006, 26:10808-10812.
32. Richter J.A., Stotz E.H., Ghetti B., Simon J.R. Comparison of alterations in tyrosine hydroxylase, dopamine levels, and dopamine uptake in the striatum of the weaver mutant mouse. Neurochem. Res. 1992, 17:437-441.
33. Roffler-Tarlov S., Graybiel A.M. Weaver mutation has differential effects on the dopamine-containing innervation of the limbic and nonlimbic striatum. Nature 1984, 307:62-66.
34. Roffler-Tarlov S., Graybiel A.M. Expression of the weaver gene in dopamine-containing neural systems is dose dependent and affects both striatal and non-striatal regions. J. Neurosci. 1986, 6:3319-3330.
35. Roffler-Tarlov S., Graybiel A.M. The postnatal development of the dopamine-containing innervation of dorsal and ventral striatum: effects of the weaver gene. J. Neurosci. 1987, 7:2364-2372.
36. Sahin B., Galdi S., Hendrick J., Greene R.W., Snyder G.L., Bibb J.A. Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling. Brain Res. 2007, 1129:1-14.
37. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.-A., Herve D., Greengard P., Fisone G. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 2007, 27:6995-7005.
38. Schiffmann S.N., Fisone G., Moresco R., Cunha R., Ferré S. Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 2007, 83:277-292.
39. Simola N., Morelli M., Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr. Pharm. Des. 2008, 14:1475-1489.
40. Simon J.R., Ghetti B. The weaver mutant mouse as a model of nigrostriatal dysfunction. Mol. Neurobiol. 1994, 9:183-189.
41. Singh N., Pillay V., Choonara Y.E. Advances in the treatment of Parkinson's disease. Prog. Neurobiol. 2007, 81:29-44.
42. Smith M.W., Cooper T.R., Joh T.H., Smith D.E. Cell loss and class distribution of TH-I cells in the substantia nigra of the neurological mutant, weaver. Brain Res. 1990, 510:242-250.
43. Svenningsson P., Lindskog M., Leden C., Parmentier M., Greengard P., Fredholm B.B., Fisone G. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. PNAS 2000, 97:1856-1860.
44. Svenningsson P., Lindskog M., Rognoni F., Fredholm B.B., Greengard P., Fisone G. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 1998, 84:223-228.
45. Sweatt J.D. Mitogen-activated protein kinases in synaptic plasticity and memory. Curr. Opin. Neurobiol. 2004, 14:311-317.
46. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:173-183.
47. Trevethick M.A., Mantell S.J., Stuart E.F., Barnard A., Wright K.N., Yeadon M. Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br. J. Pharmacol. 2008, 155:463-474.
48. Triarhou L.C. Biology and pathology of the Weaver mutant mouse. Adv. Exp. Med. Biol. 2002, 517:15-42.
49. Triarhou L.C., Norton J., Ghetti B. Mesencephalic dopamine cell deficit involves areas A8, A9 and A10 in weaver mutant mice. Exp. Brain Res. 1988, 70:256-265.
50. Verney C., Febvret-Muzerelle A., Gaspar P. Early postnatal changes of the dopaminergic mesencephalic neurons in the weaver mutant mouse. Brain Res. Dev. Brain Res. 1995, 89:115-119.
51. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
52. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44.